LONG-TERM FOLLOW-UP OF A PHASE II TRIAL OF UPFRONT BEVACIZUMAB WITH TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE, AND IRINOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)
Publication
, Conference
Ranjan, T; Desjardins, A; Peters, KB; Alderson, L; Kirkpatrick, J; Herndon, J; Bailey, L; Sampson, J; Friedman, AH; Friedman, H; Vredenburgh, J
Published in: NEURO-ONCOLOGY
October 1, 2012
Duke Scholars
Published In
NEURO-ONCOLOGY
ISSN
1522-8517
Publication Date
October 1, 2012
Volume
14
Start / End Page
81 / 82
Location
Washington, DC
Publisher
OXFORD UNIV PRESS INC
Conference Name
17th Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Ranjan, T., Desjardins, A., Peters, K. B., Alderson, L., Kirkpatrick, J., Herndon, J., … Vredenburgh, J. (2012). LONG-TERM FOLLOW-UP OF A PHASE II TRIAL OF UPFRONT BEVACIZUMAB WITH TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE, AND IRINOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM). In NEURO-ONCOLOGY (Vol. 14, pp. 81–82). Washington, DC: OXFORD UNIV PRESS INC.
Ranjan, Tulika, Annick Desjardins, Katherine B. Peters, Lloyd Alderson, John Kirkpatrick, James Herndon, Leighann Bailey, et al. “LONG-TERM FOLLOW-UP OF A PHASE II TRIAL OF UPFRONT BEVACIZUMAB WITH TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE, AND IRINOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM).” In NEURO-ONCOLOGY, 14:81–82. OXFORD UNIV PRESS INC, 2012.
Ranjan T, Desjardins A, Peters KB, Alderson L, Kirkpatrick J, Herndon J, et al. LONG-TERM FOLLOW-UP OF A PHASE II TRIAL OF UPFRONT BEVACIZUMAB WITH TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE, AND IRINOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM). In: NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2012. p. 81–2.
Ranjan, Tulika, et al. “LONG-TERM FOLLOW-UP OF A PHASE II TRIAL OF UPFRONT BEVACIZUMAB WITH TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE, AND IRINOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM).” NEURO-ONCOLOGY, vol. 14, OXFORD UNIV PRESS INC, 2012, pp. 81–82.
Ranjan T, Desjardins A, Peters KB, Alderson L, Kirkpatrick J, Herndon J, Bailey L, Sampson J, Friedman AH, Friedman H, Vredenburgh J. LONG-TERM FOLLOW-UP OF A PHASE II TRIAL OF UPFRONT BEVACIZUMAB WITH TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE, AND IRINOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM). NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2012. p. 81–82.
Published In
NEURO-ONCOLOGY
ISSN
1522-8517
Publication Date
October 1, 2012
Volume
14
Start / End Page
81 / 82
Location
Washington, DC
Publisher
OXFORD UNIV PRESS INC
Conference Name
17th Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences